Table 4

Comparison of median PFS and OS reported in the current study with that reported in literature.

AuthornRegionArmsPFS in monthsOS in monthsSecond line
received*
Rosell et al3173EuropeErlotinib 9.719.3NR
Docetaxel or gemcitabine with either cisplatin or carboplatin 5.219.576%
Zhou et al4165ChinaErlotinib13.122.8NR
Gemcitabine with carboplatin 4.627.2NR
Maemondo et al5230JapanGefitinib10.830.567.5%
Paclitaxel/carboplatin 5.423.694.6%
Mitsudomi et al6177JapanGefitinib 9.230.9NR
Docetaxel/cisplatin 6.3NRNR
Sequist et al7345East Asia, Europe, AustraliaAfatinib11.1NRNR
Pemetrexed/cisplatin 6.9NRNR
Current study290IndiaGefitinib 8.41863.8%
Pemetrexed carboplatin followed by pemetrexed maintenance5.622.693.6%
  • *The percentage of patients who received second line among patients who were eligible for same.

  • NR, not reported; OS, overall survival; PFS, progression-free survival.